Table 1 Characteristics of COPD patients in low and high SUV39H1 expression groups
Variables | Low SUV Exp. (n = 15) | High SUV Exp. (n = 15) | p value |
|---|---|---|---|
Male, n (%) | 14 (93) | 15 (100) | 1 |
Age, years; median (IQR) | 71 (64–77) | 70 (62–74) | 0.561 |
BMI; median (IQR) | 24 (23.2–26.2) | 22.7 (19.9–24.6) | 0.141 |
Cigarette smoking, n (%) | 0.413 | ||
Current smoker | 5 (33) | 8 (53) | |
Ex-smoker | 7 (47) | 6 (40) | |
Never smoker | 3 (20) | 1 (7) | |
Comorbidities, n (%) | 0.919 | ||
Heart failure | 2 (13) | 0 (0) | |
Coronary artery disease | 3 (20) | 4 (27) | |
Pulmonary hypertension | 4 (27) | 2 (13) | |
Lung cancer | 0 (0) | 0 (0) | |
Anxiety/depression | 1 (7) | 1 (7) | |
Osteoporosis | 0 (0) | 1 (7) | |
Malnutrition (BMI < 20) | 2 (13) | 4 (27) | |
Diabetes mellitus | 1 (7) | 2 (13) | |
OSA | 1 (7) | 1 (7) | |
Anemia | 2 (13) | 2 (13) | |
Lung fibrosis | 1 (7) | 0 (0) | |
Charlson comorbidity Index score; median (IQR) | 5 (3–5) | 4 (4–6) | 0.833 |
Hemogram values; median (IQR) | |||
Leukocyte count | 7800 (6300–9200) | 6600 (5950–7200) | 0.110 |
Neutrophil, % | 65 (60–71) | 59 (52–61) | 0.015* |
Eosinophil, % | 2 (1–3) | 2 (2–4) | 0.125 |
E/N Ratio, % | 3.6 (1.7–4.7) | 4.7 (3.7–7.1) | 0.071 |
Pulmonary function tests; median (IQR) | |||
Post bronchodilator FEV1/FVC,% | 62 (50–65) | 60 (55–64) | 0.868 |
Post bronchodilator FEV1, % | 57 (35–67) | 55 (40–73) | 0.934 |
COPD subtypes, n (%) | 0.966 | ||
Stage 1 | 2 (13) | 2 (13) | |
Stage 2 | 8 (54) | 7 (47) | |
Stage 3 | 2 (13) | 3 (20) | |
Stage 4 | 3 (20) | 3 (20) | |
ACO, n (%) | 0 (0) | 1 (6.7) | 1 |
Exacerbations per year; median (IQR) | 1 (0–1) | 0 (0–1) | 0.115 |